CrushSCI.com
76.5Average days
61Median days
13Fastest days
192Longest days
1872025 publications

Paper Review Records

All Paper Review Records

20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

135 days

Efficacy of Nirmatrelvir/Ritonavir in High-Risk Adults with Preexisting SARS-CoV-2 Immunity: A Pooled Analysis of Two Randomized Controlled Trials

Authors
Heidi Leister-Tebbe; John M. McLaughlin; Weihang Bao; Romina Quercia; Wayne Wisemandle; Jennifer HammondShow moreShow less
Affiliations
1. Pfizer Research & Development, Pfizer Inc, Collegeville, USA; 2. Pfizer Research & Development, Pfizer Inc, New York, USA; 3. Chief Medical Affairs Office, Pfizer Inc, New York, USA; 4. Pfizer Research & Development, Pfizer Inc, Lake Forest, USAShow moreShow less
Source PDF DOI Publisher page
83 days

Comparative Effectiveness and Hematological Safety of Linezolid and Tedizolid in Bone and Joint Infections: A Retrospective Cohort Study

Authors
Charlène Aïn; Paul Laffont-Lozes; Albert Sotto; Julien Mazet; Aurélie Martin; Adeline Dubois; Nicolas Cellier; Paul Loubet; Romaric LarcherShow moreShow less
Affiliations
1. Infectious and Tropical Diseases Department, Caremeau University Hospital, Nimes University Hospital, Nîmes, France; 2. Department of Pharmacy, Nimes University Hospital, Nîmes, France; 3. VBIC (Bacterial Virulence and Chronic Infection), INSERM (French Institute of Health and Medical Research), University of Montpellier, Nîmes, France; 4. Department of Microbiology and Hospital Hygiene, Nimes University Hospital, Nîmes, France; 5. Department of Orthopedic Surgery and Traumatology, Nimes University Hospital, Nîmes, France; 6. PhyMedExp (Physiology and Experimental Medicine), INSERM (French Institute of Health and Medical Research), CNRS (French National Centre for Scientific Research), University of Montpellier, Montpellier, FranceShow moreShow less
Source PDF DOI Publisher page
30 days

Sofosbuvir/Velpatasvir Failure in Hepatitis C Subtype 6f: A Paired Virological Analysis Before and After Therapy

Authors
Duong Hoang Huy Le; Pornjarim Nilyanimit; Jiratchaya Puenpa; Wijittra Phaengkha; Chakhrit Arpornphet; Saranya Ngamnimit; Mayuree Chantho; Jidapa Suwannachat; Nitiya Srisuk; Sittisak Honsawek; Yong PoovorawanShow moreShow less
Affiliations
1. Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2. Medical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3. Medical Biochemistry and Molecular Biology Department, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; 4. Biomedical Research and Diagnostics Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; 5. Nam Nao Hospital, Nam Nao District, Thailand; 6. Phetchabun Provincial Public Health Office, Phetchabun, Thailand; 7. Lomsak Hospital, Lomsak, Thailand; 8. Phetchabun Hospital, Mueang Phetchabun, Thailand; 9. Nongphai Hospital, Nong Phai, Thailand; 10. Lomkao Crown Prince Hospital, Lom Kao, Thailand; 11. Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 12. Fellow of the Royal Society of Thailand (FRS[T]), Bangkok, ThailandShow moreShow less
Source PDF DOI Publisher page
51 days

Rise of Lower Respiratory Tract Infections Other than Respiratory Syncytial Virus in the Emergency Room: Results from the Season (2024/25) of the RISE Study

Authors
Maria Adams; Vivien Greese; Anissa Paschereit; Tamina Schenck; Julia Kristin Singer; Johannes Paul Paulick; Rafael Paolo Pricoco; Hermann Girschick; Eva Jenz; Martina Rabe; Marta Gil-Pawlak; Christine Ginocchio; Christine Hagemann; Tobias TenenbaumShow moreShow less
Affiliations
1. Sana Klinikum Lichtenberg Berlin, Clinic for Child and Adolescent Medicine, Academic Teaching Hospital Charité-Universitätsmedizin Berlin, Berlin, Germany; 2. Children’s Hospital, Vivantes Klinikum Friedrichshain, Berlin, Germany; 3. ZEG – Berlin Center for Epidemiology and Health Research, Berlin, Germany; 4. Stat-Dx Life (QIAGEN), Barcelona, Spain; 5. SANOFI Vaccines, Berlin, GermanyShow moreShow less
Source PDF DOI Publisher page
137 days

Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate Vaccine

Authors
Santosh Taur; Namrata Kulkarni; Sachin Choudhari; Ahuva Averin; Anu Suokas; Mary MacKinnon; Mark Atwood; Liping HuangShow moreShow less
Affiliations
1. Pfizer Ltd, Mumbai, India; 2. Avalere Health, Washington, USA; 3. Global Value and Evidence, Pfizer Inc, Collegeville, USAShow moreShow less
Source PDF DOI Publisher page
46 days

Postpandemic Social Contact Patterns: A Cross-Sectional Survey in Japan, South Korea, Thailand, and Vietnam

Authors
June Young Chun; Yunseop Shin; Yongdai Kim; Shinya TsuzukiShow moreShow less
Affiliations
1. Department of Internal Medicine, National Cancer Center, Goyang, South Korea; 2. Department of Statistics, Seoul National University, Seoul, South Korea; 3. Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan; 4. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BelgiumShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Infectious Diseases and Therapy take to review a manuscript?

As of 2026-11-18, CrushSCI has 20 complete review records for Infectious Diseases and Therapy. The fastest paper went from submission to acceptance in 13 days (Response Letter to ‘Letter to the Editor Regarding Complementary Strategy of Maternal Immunization and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment’, received 2026-05-22, accepted 2026-06-04); the slowest took 192 days. The average is 76.5 days and the median is 61 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.